Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation

Launched by KAOHSIUNG MEDICAL UNIVERSITY · Oct 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different concentrations of a medication called Remifentanil affect pain control during a procedure known as uterine fibroid ablation. The main goal is to determine whether a higher concentration of 2.0 ng/mL provides better pain relief compared to a lower concentration of 1.0 ng/mL, while also checking for any side effects. Participants will be women aged 20 to 65 who have been diagnosed with uterine fibroids. They will be divided into two groups, and during the procedure, their pain levels and vital signs will be monitored.

To be eligible for the study, participants should be healthy enough according to specific guidelines and must not have certain medical conditions, such as heart disease or chronic kidney issues. The trial is not yet recruiting participants, but if you qualify, you can expect to be part of an important research effort aimed at improving pain management for women undergoing this common procedure. Your experience will help doctors understand how to provide better care in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Aged between 20 and 65 years old
• • American Society of Anesthesiology classification I\~III
• • Female patients diagnosed with uterine fibroids by obstetricians and gynecologists
• Exclusion Criteria:
• • 1. Patients with heart disease (such as arrhythmia or severe ventricular dysfunction)
• • 2. Patients with chronic kidney disease in stage III or above or dialysis patients
• • 3. Long-term alcohol addiction or drug abuse
• • 4. Patients with abnormal liver index or chronic hepatitis
• • 5. Those who are allergic Remifentanil
• • 6. Those who refuse to participate in the experiment